Veracyte Signs a Multi-Year Agreement with AstraZeneca

 Veracyte Signs a Multi-Year Agreement with AstraZeneca

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia


  • Veracyte collaborates with Acerta Pharma, a hematology research and development of AstraZeneca for providing genomic information for supporting development of oncology therapeutics
  • On Dec 03, 2019 the company reported acquisition of its diagnostics rights to the NanoString nCounter platform and genomic tests for breast cancer and lymphoma
  • The focus of the agreement is to expand the global footprints and the capability to treat cancer

Click here to read full press release/ article | Ref: Veracyte | Image: Signbox

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post